Dengue Virus

AAK1-IN-6 is a potent inhibitor of AP-2-associated protein kinase 1 (AAK1) with an IC50 value of 12 nM. This compound exhibits significant antiviral activity against dengue virus (DNEV2, EC50 = 0.24 μM) and Venezuelan equine encephalitis virus (VEEV, EC50 = 0.30 μM). AAK1-IN-6 is a valuable tool for researchers investigating antiviral mechanisms and potential therapeutic strategies.

5-((1H-Indol-3-yl)methylene)imidazolidine-2,4-dione is a potent inhibitor of the dengue virus NS2B-NS3 protease and thrombin. This compound is valuable for studying the mechanisms of viral replication and coagulation processes, making it an essential tool in research focused on infectious diseases and related therapeutic interventions. Its dual activity highlights its potential for investigating the dynamics of viral pathology and thrombotic complications.

(-)-JNJ-A07 is a potent and selective inhibitor of Dengue Virus (DENV) with an EC50 value of 31 nM. It demonstrates significant antiviral activity, making it a valuable tool for research in virology and the study of DENV pathogenesis. This compound is suitable for investigations into potential therapeutic strategies for dengue fever and other flavivirus-related diseases.

SDM25N hydrochloride is a potent δ-opioid receptor antagonist that also serves as an effective inhibitor of the dengue virus (DENV). It specifically targets the viral NS4B protein, significantly limiting genomic RNA replication. This compound presents valuable opportunities for research on antiviral strategies and the role of δ-opioid receptors in viral pathogenesis.

NSC-323241 is an STT3A-mediated mega protein complex assembly inhibitor that effectively disrupts the endoplasmic reticulum (ER) mega complex essential for dengue virus (DENV) and Zika virus (ZIKV) infection. By targeting the interaction between the STT3A subcomplex, viral nonstructural proteins (e.g., NS2B, NS3), and host translocon proteins, NSC-323241 impedes the establishment of the viral replication microenvironment. This compound is valuable for investigating the mechanisms of flavivirus infections, including dengue fever and Zika virus.

IRBM-Z-1 is a non-competitive inhibitor targeting the Zika virus (ZIKV) NS2B-NS3 protease, demonstrating an IC50 of 1.8 μM. This compound also effectively inhibits the NS2B-NS3 proteases of T156I-mutated dengue virus 2 (DENV2) and West Nile virus (WNV), with IC50 values of 3.9 μM and 4.7 μM, respectively. IRBM-Z-1 is capable of inhibiting ZIKV replication and reducing virus-induced cytopathic effects, making it a valuable tool for research focused on ZIKV infection and associated viral pathogenesis.

IRBM-Z-2 is an orally active, non-competitive inhibitor targeting the Zika virus (ZIKV) NS2B-NS3 protease, demonstrating IC50 values of 0.04 μM for the wild-type and 3.1 μM for the I156T mutant strains. This compound exhibits broad-spectrum activity against flaviviruses, with IC50 values of 2.1 μM and 0.09 μM against the NS2B-NS3 proteases of dengue virus serotype 2 (DENV2) and West Nile virus (WNV), respectively. IRBM-Z-2 effectively inhibits ZIKV replication and mitigates virus-induced cytopathic effects, making it a valuable tool for research on ZIKV infection and the study of flavivirus-related diseases.

RBT-9 is a COVID-19 inhibitor that targets viral replication and inflammation pathways. It has demonstrated efficacy in preventing the progression to severe COVID-19 and associated organ failure. Furthermore, RBT-9 exhibits antiviral activity against various enveloped viruses, including influenza, hepatitis C virus (HCV), dengue, and yellow fever, making it a valuable tool for research in viral pathogenesis and therapeutic intervention.

CM-10-18 is a potent inhibitor of α-glucosidases I and II, demonstrating significant activity in vitro and in animal models. This compound also exhibits antiviral properties by inhibiting dengue virus (DENV) infection in cultured human cells, while effectively reducing peak viremia in mice. CM-10-18 is valuable for research applications related to glycosidase inhibition and viral pathogenesis.